SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
X	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* F2 Bioscience IV L.P. (Last) (First) (Middle) UGLAND HOUSE, SOUTH CHURCH STREET PO BOX 309 (Street) GEORGE TOWN E9 KY1-1104 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Radius Health, Inc. [ RDUS ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 01/16/2015
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/16/2015		J		1,794,983(1)	D	(1)	0	D(2)
Common Stock	01/16/2015		J		871,851(3)	D	(3)	0	I	By Fund(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock Warrant	$2.694	01/16/2015		J			249,932(1)	02/14/2014	02/14/2019	Common Stock	249,932(1)	$0	0	D(2)
Common Stock Warrant	$2.694	01/16/2015		J			121,396(3)	02/14/2014	02/14/2019	Common Stock	121,396(3)	$0	0	I	By Fund(4)

1. Name and Address of Reporting Person* F2 Bioscience IV L.P. (Last) (First) (Middle) UGLAND HOUSE, SOUTH CHURCH STREET PO BOX 309 (Street) GEORGE TOWN E9 KY1-1104 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* F2 Bioscience IV GP Ltd. (Last) (First) (Middle) UGLAND HOUSE, SOUTH CHURCH STREET PO BOX 309 (Street) GEORGE TOWN E9 KY1-1104 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* F2 Capital Ltd (Last) (First) (Middle) PO BOX 3175 ROAD TOWN (Street) TORTOLA D8 VG 1110 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* Priestley Katherine (Last) (First) (Middle) UGLAND HOUSE, SOUTH CHURCH STREET PO BOX 309 (Street) GEORGE TOWN E9 KY1-1104 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* F2 Bio Ventures V L.P. (Last) (First) (Middle) KINGSTON CHAMBERS P.O. BOX 173 (Street) ROAD TOWN, TORTOLA D8 VG 1110 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* F2 Bio Ventures GP Ltd. (Last) (First) (Middle) KINGSTON CHAMBERS P.O. BOX 173 (Street) ROAD TOWN, TORTOLA D8 VG 1110 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* Globeways Holdings Ltd (Last) (First) (Middle) 3RD FLOOR, GENEVE PLACE WATERFRONT DRIVE, PO BOX 3175 (Street) ROAD TOWN, TORTOLA D8 00000 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

Explanation of Responses:

1. Reflects a liquidating pro rata distribution by F2 Bioscience IV L.P. ("F2 IV") to its limited and general partners.

2. The reported securities are owned directly by F2 IV. F2 Bioscience IV GP Ltd. ("F2 IV GP") is the General Partner of F2 IV. Katherine Priestley and Globeways Holdings Limited ("Globeways") are members of F2 IV GP. F2 Capital Limited ("F2 Capital") is an investment adviser to F2 IV. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

3. Reflects a liquidating pro rata distribution by F2 Bio Ventures V L.P. ("F2 Bio") to its limited and general partners.

4. The reported securities are owned directly by F2 Bio. F2 Bio Ventures GP Ltd. is the General Partner of F2 Bio. Globeways is the sole member of F2 Bio Ventures GP Ltd. F2 Capital is an investment adviser to F2 Bio. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

	/s/ Morag Law, attorney-in-fact for F2 Bioscience IV, L.P.	01/16/2015
	/s/ Morag Law, attorney-in-fact for F2 Bioscience IV GP Ltd.	01/16/2015
	/s/ Morag Law, attorney-in-fact for F2 Capital Limited	01/16/2015
	/s/ Morag Law, attorney-in-fact for Katherine Priestley	01/16/2015
	/s/ Morag Law, attorney-in-fact for F2 Bio Ventures V, L.P.	01/16/2015
	/s/ Morag Law, attorney-in-fact for F2 Bio Ventures GP Ltd.	01/16/2015
	/s/ Morag Law, attorney-in-fact for Globeways Holdings Ltd.	01/16/2015
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.